Vazquez Juan C, Abalos Edgardo
Departamento de Salud Reproductiva, Instituto Nacional de Endocrinologia (INEN), Zapata y D, Vedado, Habana, Cuba, 10 400.
Cochrane Database Syst Rev. 2011 Jan 19;2011(1):CD002256. doi: 10.1002/14651858.CD002256.pub2.
Urinary tract infections, including pyelonephritis, are serious complications that may lead to significant maternal and neonatal morbidity and mortality. There is a large number of drugs, and combination of them, available to treat urinary tract infections, most of them tested in non-pregnant women. Attempts to define the optimal antibiotic regimen for pregnancy have, therefore, been problematic.
The objective of this review was to determine, from the best available evidence from randomised controlled trials, which agent is the most effective for the treatment of symptomatic urinary tract infections during pregnancy in terms of cure rates, recurrent infection, incidence of preterm delivery and premature rupture of membranes, admission to neonatal intensive care unit, need for change of antibiotic, and incidence of prolonged pyrexia.
We searched the Cochrane Pregnancy and Childbirth Group Trials Register (November 2009) and reference lists of articles.
We considered all trials where the intention was to allocate participants randomly to one of at least two alternative treatments for any symptomatic urinary tract infection.
Both review authors assessed trial quality and extracted data.
We included 10 studies, recruiting a total of 1125 pregnant women. In most of the comparisons there were no significant differences between the treatments under study with regard to cure rates, recurrent infection, incidence of preterm delivery, admission to neonatal intensive care unit, need for change of antibiotic and incidence of prolonged pyrexia. When cefuroxime and cephradine were compared, there were better cure rates (29/49 versus 41/52) and fewer recurrences (20/49 versus 11/52) in the cefuroxime group. There was only one other statistically significant difference when comparing outpatient versus inpatient treatment. Gestational age at birth was greater in women from the outpatient group (38.86 versus 37.21), while birthweight was on average greater in the inpatient group (3120 versus 2659).
AUTHORS' CONCLUSIONS: Although antibiotic treatment is effective for the cure of urinary tract infections, there are insufficient data to recommend any specific drug regimen for treatment of symptomatic urinary tract infections during pregnancy. All the antibiotics studied were shown to be very effective in decreasing the incidence of the different outcomes. Complications were very rare. All included trials had very small sample sizes to reliably detect important differences between treatments. Future studies should evaluate the most promising antibiotics, in terms of class, timing, dose, acceptability, maternal and neonatal outcomes and costs.
包括肾盂肾炎在内的尿路感染是严重的并发症,可能导致孕产妇和新生儿出现显著的发病和死亡情况。有大量药物及其联合用药可用于治疗尿路感染,其中大多数在非孕妇中进行过测试。因此,确定孕期最佳抗生素治疗方案一直存在问题。
本综述的目的是根据随机对照试验的最佳现有证据,确定就治愈率、复发性感染、早产和胎膜早破发生率、入住新生儿重症监护病房、更换抗生素的必要性以及长期发热发生率而言,哪种药物对治疗孕期有症状的尿路感染最有效。
我们检索了Cochrane妊娠与分娩组试验注册库(2009年11月)以及文章的参考文献列表。
我们纳入了所有旨在将参与者随机分配至至少两种治疗有症状尿路感染的替代治疗方法之一的试验。
两位综述作者评估了试验质量并提取了数据。
我们纳入了10项研究,共招募了1125名孕妇。在大多数比较中,所研究的治疗方法在治愈率、复发性感染、早产发生率、入住新生儿重症监护病房、更换抗生素的必要性以及长期发热发生率方面没有显著差异。当比较头孢呋辛和头孢拉定时,头孢呋辛组的治愈率更高(29/49对41/52),复发率更低(20/49对11/52)。在比较门诊治疗与住院治疗时,仅存在另一个统计学上的显著差异。门诊组女性的出生孕周更大(38.86对37.21),而住院组的出生体重平均更大(3120对2659)。
尽管抗生素治疗对治愈尿路感染有效,但尚无足够数据推荐孕期有症状尿路感染的任何特定药物治疗方案。所有研究的抗生素在降低不同结局的发生率方面均显示非常有效。并发症非常罕见。所有纳入的试验样本量都非常小,无法可靠地检测出治疗方法之间的重要差异。未来的研究应从类别、时机、剂量、可接受性、孕产妇和新生儿结局以及成本等方面评估最有前景的抗生素。